Drug prices A smaller window toraise drug prices could lead drugmakers to look for other ways togenerate growth, including M&A deals. (Photo:Shutterstock)

Washington wants drug prices to fall. Wall Street wants stock prices to rise. For some of the world'slargest pharmaceutical companies, pleasing both sidescould be a problem.

Last year, the industry promised restraint after PresidentDonald Trump took aim at rising pharmaceutical costs. OnJan. 1, drugmakers returned to their annual practice of regularincreases, boosting prices for dozens of treatments, fromhot-selling arthritis therapies to painkillers at the center of theU.S. opioid epidemic.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.